Search Result

Results for "

acute myocardial ischemia

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Adenosine Receptor (2) AMPK (3) Apoptosis (5) Autophagy (2) Bcl-2 Family (1) Calcium Channel (2) Interleukin Related (3) JAK (1) Keap1-Nrf2 (2) MMP (1) Na+/H+ Exchanger (NHE) (1) NF-κB (4) NOD-like Receptor (NLR) (5) PARP (2) PKC (2) PPAR (1) Prostaglandin Receptor (3) Pyroptosis (3) Reactive Oxygen Species (ROS) (1) Reference Standards (2) Sirtuin (2) SOD (1) STAT (1) TNF Receptor (1) TREM receptor (2)
By Research Areas:	Cancer (2) Cardiovascular Disease (14) Inflammation/Immunology (8) Metabolic Disease (3)

By Targets:

Adenosine Receptor (2)

AMPK (3)

Apoptosis (5)

Autophagy (2)

Bcl-2 Family (1)

Calcium Channel (2)

Interleukin Related (3)

JAK (1)

Keap1-Nrf2 (2)

MMP (1)

Na+/H+ Exchanger (NHE) (1)

NF-κB (4)

NOD-like Receptor (NLR) (5)

PARP (2)

PKC (2)

PPAR (1)

Prostaglandin Receptor (3)

Pyroptosis (3)

Reactive Oxygen Species (ROS) (1)

Reference Standards (2)

Sirtuin (2)

SOD (1)

STAT (1)

TNF Receptor (1)

TREM receptor (2)

By Research Areas:

Cancer (2)

Cardiovascular Disease (14)

Inflammation/Immunology (8)

Metabolic Disease (3)

Inhibitors & Agonists

Peptides

Natural
Products

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-106262B

Delcasertib hydrochloride 3 Publications Verification KAI-9803 hydrochloride; BMS-875944 hydrochloride	PKC	Cardiovascular Disease Inflammation/Immunology
Delcasertib (KAI-9803) hydrochloride is a potent and selective δ-protein kinase C (δPKC) inhibitor. Delcasertib (KAI-9803) hydrochloride could ameliorate injury associated with ischemia and reperfusion in animal models of acute myocardial infarction (MI) .

HY-W011082

NLRP3-IN-2	NOD-like Receptor (NLR)	Cardiovascular Disease
NLRP3-IN-2, an intermediate substrate in the synthesis of glyburide, inhibits the formation of the NLRP3 inflammasome in cardiomyocytes and limits the infarct size following myocardial ischemia/reperfusion in the mouse, without affecting glucose metabolism .

HY-17436

Clevidipine	Calcium Channel	Cardiovascular Disease Cancer
Clevidipine is a selective, short-acting L-type calcium channel antagonist with an IC₅₀ of 7.1 nM. Clevidipine can competitively bind to calcium channels and exert rapid vasoselective vasodilation by blocking the influx of extracellular calcium ions, thereby reducing peripheral vascular resistance and effectively controlling acute severe hypertension. Clevidipine can also protect the myocardium from reperfusion injury by promoting the release of nitric oxide (NO). Clevidipine can be used in the research of acute hypertension, perioperative blood pressure management, and myocardial ischemia-reperfusion injury .

HY-P3211

Nangibotide 3 Publications Verification LR12	TREM receptor NF-κB NOD-like Receptor (NLR) Interleukin Related Apoptosis	Cardiovascular Disease Inflammation/Immunology
Nangibotide (LR12) is a synthetic peptide and TREM-1 receptor inhibitor. Nangibotide inhibits NF-κB and NLRP3 inflammasome activation and reduces the release of pro-inflammatory factors (such as IL-1β, IL-8). Nangibotide inhibits Apoptosis. Nangibotide reduces excessive inflammatory responses and protects tissues (liver, lung) from damage. Nangibotide can be used in the researches for myocardial ischemia-reperfusion injury, septic shock, acute lung injury, osteoarthritis, and acute liver failure .

HY-108972

SQ 29548	Prostaglandin Receptor	Metabolic Disease
SQ 29548, a high affinity radioligand, is a selective thromboxane-prostanoid (TP) receptor antagonist .

HY-P3211A

Nangibotide TFA 3 Publications Verification LR12 TFA	TREM receptor NF-κB NOD-like Receptor (NLR) Interleukin Related Apoptosis	Cardiovascular Disease Inflammation/Immunology
Nangibotide TFA (LR12 TFA) is a synthetic peptide and TREM-1 receptor inhibitor. Nangibotide TFA inhibits NF-κB and NLRP3 inflammasome activation and reduces the release of pro-inflammatory factors (such as IL-1β, IL-8). Nangibotide TFA inhibits Apoptosis. Nangibotide TFA reduces excessive inflammatory responses and protects tissues (liver, lung) from damage. Nangibotide TFA can be used in the researches for myocardial ischemia-reperfusion injury, septic shock, acute lung injury, osteoarthritis, and acute liver failure .

HY-W714710

Teopranitol KC-046	Prostaglandin Receptor	Cardiovascular Disease
Teopranitol (KC-046), a coronary vasodilator with a rather selective venous dilatation, is used for the study of the acute myocardial ischemia .

HY-114671

Taprostene CG-4203	Prostaglandin Receptor	Cardiovascular Disease
Taprostene (CG-4203) is a synthetic, chemically stable analogue of Prostacyclin (PGI2). Taprostene exhibits endothelium and myocardial protecting actions after acute myocardial ischemia and reperfusion in cats. Taprostene enhances cytoprotective actions, while minimizing unwanted hemodynamic effects .

HY-125144

BIIB 513	Na+/H+ Exchanger (NHE)	Cardiovascular Disease
BIIB 513 is an inhibitor of NHE 1 that protects against myocardial ischemia. BIIB 513 inhibits acid load recovery with an IC₅₀ of 27 nmol/L in cells expressing wild-type NHE 1 under acute acid load .

HY-106262

Delcasertib KAI-9803; BMS-875944	PKC	Cardiovascular Disease Inflammation/Immunology
Delcasertib (KAI-9803) is a potent and selective δ-protein kinase C (δPKC) inhibitor. Delcasertib (KAI-9803) could ameliorate injury associated with ischemia and reperfusion in animal models of acute myocardial infarction (MI) .

HY-103171R

BAY 60-6583 (Standard)	Reference Standards Adenosine Receptor	Cardiovascular Disease Inflammation/Immunology
BAY 60-6583 (Standard) is the analytical standard of BAY 60-6583. This product is intended for research and analytical applications. BAY 60-6583 is a potent and high-affinity agonist of adenosine A2B receptor (EC50?= 3 nM) over A1, A2A, and A3 receptors. BAY 60-6583 binds to mouse, rabbit, and dog A2BAR with Ki values of 750 nM, 340 nM and 330 nM, respectively. BAY 60-6583 has a cardioprotective effect in a myocardial ischemia model .

HY-103171

BAY 60-6583 5 Publications Verification	Adenosine Receptor	Cardiovascular Disease Inflammation/Immunology
BAY 60-6583 is a potent and high-affinity agonist of adenosine A_2B receptor (EC₅₀=3 nM) over A1, A2A, and A3 receptors. BAY 60-6583 binds to mouse, rabbit, and dog A2BAR with K_i values of 750 nM, 340 nM and 330 nM, respectively. BAY 60-6583 has a cardioprotective effect in a myocardial ischemia model .

HY-117970

MMPI-1154	MMP	Cardiovascular Disease
MMPI-1154 is a promising novel cardio-cytoprotective imidazole-carboxylic acid (ICA) MMP-2 inhibitor(IC₅₀=6.6 μM) and can be used for the study of acute myocardial infarction. MMPI-1154 also inhibits the activity of MMP-13, MMP-1 and MMP-9 with IC₅₀s of 1.8 μM,10 μM, and 13 μM, respectively .

HY-N0806

Sweroside 1 Publications Verification	Keap1-Nrf2 AMPK Sirtuin NF-κB NOD-like Receptor (NLR) Pyroptosis Apoptosis Autophagy PARP	Cardiovascular Disease Metabolic Disease Inflammation/Immunology Cancer
Sweroside is an iridoid glycoside that targets multiple targets, including the Keap1/Nrf2 axis, NLRP3 inflammasome, SIRT1, NF-κB, AMPK/mTOR pathway, and caspase family. Sweroside promotes Nrf2 nuclear translocation by competitively binding to Keap1. Sweroside also inhibits oxidative stress and NLRP3-mediated pyroptosis by activating Nrf2, inhibits NF-κB inflammatory pathway by activating SIRT1, and promotes autophagy and induces caspase-dependent apoptosis via the AMPK/mTOR pathway. Sweroside has antioxidant, anti-inflammatory, anti-apoptotic, and lipid metabolism regulating activities, and can be used in the research of myocardial ischemia-reperfusion injury, leukemia, acute lung injury, non-alcoholic fatty liver disease, and other fields .

HY-N6850

Calenduloside E 1 Publications Verification	Apoptosis Pyroptosis AMPK Bcl-2 Family JAK STAT Calcium Channel Interleukin Related TNF Receptor SOD Reactive Oxygen Species (ROS) PPAR	Cardiovascular Disease Inflammation/Immunology
Calenduloside E is a pentacyclic triterpenoid saponin that can be extracted from the bark and roots of Aralia ovata, and has anti-inflammatory and anti-apoptotic activities. Calenduloside E alleviates atherosclerosis by regulating macrophage polarization, improves mitochondrial function by regulating the AMPK-SIRT3 pathway, and alleviates acute liver injury. In addition, Calenduloside E promotes the interaction between L-type calcium channels and Bcl-2 related apoptosis genes, inhibits calcium overload, and alleviates myocardial ischemia/reperfusion injury. Calenduloside E also improves non-alcoholic fatty liver disease by regulating heat shock-dependent pathways, and inhibits ROS mediated JAK1-STAT3 pathways to reduce cellular inflammatory responses .

HY-N0806R

Sweroside (Standard)	Reference Standards Keap1-Nrf2 AMPK Sirtuin NF-κB NOD-like Receptor (NLR) Pyroptosis Apoptosis Autophagy PARP	Metabolic Disease
Sweroside (Standard) is the analytical standard of Sweroside (HY-N0806). This product is intended for research and analytical applications. Sweroside is an iridoid glycoside that targets multiple targets, including the Keap1/Nrf2 axis, NLRP3 inflammasome, SIRT1, NF-κB, AMPK/mTOR pathway, and caspase family. Sweroside promotes Nrf2 nuclear translocation by competitively binding to Keap1. Sweroside also inhibits oxidative stress and NLRP3-mediated pyroptosis by activating Nrf2, inhibits NF-κB inflammatory pathway by activating SIRT1, and promotes autophagy and induces caspase-dependent apoptosis via the AMPK/mTOR pathway. Sweroside has antioxidant, anti-inflammatory, anti-apoptotic, and lipid metabolism regulating activities, and can be used in the research of myocardial ischemia-reperfusion injury, leukemia, acute lung injury, non-alcoholic fatty liver disease, and other fields .

Cat. No.	Product Name	Target	Research Area